Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Accured Expenses (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Change in Accured Expenses for 6 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 404.97% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, up 173.63% year-over-year, with the annual reading at $2.6 million for FY2025, 173.63% up from the prior year.
  • Change in Accured Expenses hit $3.6 million in Q4 2025 for Insight Molecular Diagnostics, up from $1.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.6 million in Q4 2025 to a low of -$3.1 million in Q2 2025.
  • Historically, Change in Accured Expenses has averaged -$109750.0 across 5 years, with a median of $154500.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 12576.19% in 2023 and later surged 415.08% in 2024.
  • Year by year, Change in Accured Expenses stood at $244000.0 in 2021, then tumbled by 151.23% to -$125000.0 in 2022, then tumbled by 351.2% to -$564000.0 in 2023, then surged by 224.82% to $704000.0 in 2024, then skyrocketed by 404.97% to $3.6 million in 2025.
  • Business Quant data shows Change in Accured Expenses for IMDX at $3.6 million in Q4 2025, $1.2 million in Q3 2025, and -$3.1 million in Q2 2025.